A newly published study reveals that a protein called DHHC3 actively suppresses the immune system's ability to fight melanoma, suggesting that blocking this protein could enhance the body's natural cancer-fighting defenses. Scientists at Dana-Farber Cancer Institute found that when they eliminated DHHC3 from melanoma cells in laboratory and animal models, tumors shrank significantly, but only when the immune system was intact and able to respond.

What Is DHHC3 and Why Does It Matter in Melanoma?

DHHC3 is a protein that regulates how other proteins are modified inside cells, a process called palmitoylation. It also helps maintain the balance of reactive molecules within cells. Previous research had linked high levels of DHHC3 to poor outcomes in several cancer types, but its specific role in melanoma and immune evasion remained a mystery until now.

Melanoma is one of the most aggressive forms of skin cancer and is heavily influenced by the complex interactions between tumor cells and the immune system. Modern immunotherapies have transformed treatment for many patients, yet researchers continue searching for the molecular mechanisms that allow tumors to hide from immune attack and keep growing.

How Did Researchers Test DHHC3's Role?

The research team, led by first author and corresponding author Chandan Sharma and corresponding author Martin E. Hemler from the Department of Cancer Immunology and Virology at Dana-Farber Cancer Institute, used CRISPR gene editing to remove DHHC3 from melanoma cells. The results were striking: when DHHC3 was eliminated, cells experienced increased oxidative stress and cellular senescence, a state where cells stop dividing and begin to deteriorate.

The most telling findings emerged when researchers studied these modified cells in living mice. Melanoma cells lacking DHHC3 formed significantly smaller tumors in immunocompetent mice, which have fully functional immune systems. However, tumor growth was not significantly reduced in immunodeficient mice lacking functional immune responses. This critical difference revealed that DHHC3 loss works primarily by activating the immune system rather than directly damaging tumor cells.

What Changes Occurred in the Tumor Immune Environment?

When DHHC3 was removed from melanoma cells, the tumor's immune microenvironment underwent dramatic changes. The research revealed substantial increases in several types of immune cells that fight cancer:

• Natural Killer Cells: These immune cells patrol the body and kill abnormal cells, including cancer cells, without requiring prior sensitization.
• M1 Macrophages: These are immune cells that actively attack tumors and promote anti-cancer inflammation.
• CD4-Positive T Cells: These helper T cells coordinate immune responses and enhance the effectiveness of other immune cells.
• CD8-Positive T Cells: These cytotoxic T cells directly kill cancer cells by recognizing tumor-specific markers.

At the same time, populations of pro-tumor immune cells decreased significantly. M2 macrophages and myeloid-derived suppressor cells (MDSCs), which typically support tumor growth and suppress anti-cancer immunity, were reduced in DHHC3-deficient tumors.

What Are the Implications for Melanoma Treatment?

These findings open a new avenue for melanoma treatment by identifying DHHC3 as a potential therapeutic target. Rather than directly killing cancer cells, blocking DHHC3 appears to remove a molecular brake that tumors use to suppress immune attack. This approach aligns with the growing field of immunotherapy, which works by unleashing the body's own defenses rather than relying solely on toxic drugs.

The discovery is particularly significant because it addresses a fundamental challenge in cancer treatment: tumors are remarkably skilled at evading immune detection. By understanding how DHHC3 enables this evasion, researchers may be able to develop new drugs that restore the immune system's ability to recognize and destroy melanoma cells.

The research was published in Volume 17 of Oncotarget on June 8, 2026, in a peer-reviewed study titled "DHHC3 interferes with antitumor immunity in melanoma cells." While these results are promising, they represent early-stage laboratory and animal research. Further studies will be needed to determine whether blocking DHHC3 is safe and effective in human patients with melanoma.